Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: A multicenter prospective study by the Acid-Related Symptom Research Group in Japan

Journal of Gastroenterology

Volumn 46, Issue 11, 2011, Pages 1273-1283

  Furuta, Takahisa ^a   Shimatani, Tomohiko ^b   Sugimoto, Mitsushige ^a   Ishihara, Shunji ^c   Fujiwara, Yasuhiro ^d   Kusano, Motoyasu ^e   Koike, Tomoyuki ^f   Hongo, Michio ^g   Chiba, Tsutomu ^h   Kinoshita, Yoshikazu ^c  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^c SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e GUNMA UNIVERSITY HOSPITAL   (Japan)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g TOHOKU UNIVERSITY HOSPITAL   (Japan)

^h KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

FSSG; GERD; NERD; Rabeprazole

Indexed keywords

RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FREQUENCY SCALE FOR SYMPTOM OF GASTROESOPHAGEAL REFLUX; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON EROSIVE REFLUX DISEASE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; REFLUX ESOPHAGITIS; SEX DIFFERENCE; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ESOPHAGITIS, PEPTIC; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84655169248     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0446-2     Document Type: Article

References (24)

1. ML Cloud N Enas TJ Humphries S Bassion 1998 Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD) Dig Dis Sci 43 5 993 1000 (Pubitemid 28211458)
2. Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L, FAST Trial Investigators. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther. 2002;16(3):445-54 (Erratum in: Aliment Pharmacol Ther. 2002;16(5):1035). (Pubitemid 34214523)
3. P Miner Jr W Orr J Filippone L Jokubaitis S Sloan 2002 Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial Am J Gastroenterol 97 6 1332 1339 (Pubitemid 34664773)
4. H Miwa M Sasaki T Furuta T Koike Y Habu M Ito 2007 Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan Aliment Pharmacol Ther 26 1 69 77 (Pubitemid 46889840)
5. M Miyamoto K Haruma K Takeuchi M Kuwabara 2008 Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy J Gastroenterol Hepatol 23 5 746 751 (Pubitemid 351519424)
6. R Fass 2009 Proton pump inhibitor failure-what are the therapeutic options? Am J Gastroenterol 104 Suppl 2 S33 S38
7. AJ Bredenoord AJ Smout 2008 Refractory gastrooesophageal reflux disease Eur J Gastroenterol Hepatol 20 3 217 223 (Pubitemid 351317360)
8. T Hershcovici R Fass 2010 Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors Curr Opin Gastroenterol 26 4 367 378
9. M Hongo 2006 Minimal changes in reflux esophagitis: red ones and white ones J Gastroenterol 41 2 95 99
10. N Uemura H Inokuchi H Serizawa T Chikama M Yamauchi T Tsuru 2008 Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease J Gastroenterol 43 9 670 678
11. Y Fujiwara K Higuchi H Nebiki S Chono H Uno K Kitada 2005 Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease Aliment Pharmacol Ther 21 Suppl 2 10 18 (Pubitemid 40806575)
12. T Furuta N Shirai F Watanabe S Honda K Takeuchi T Iida 2002 Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole Clin Pharmacol Ther 72 4 453 460 (Pubitemid 35178870)
13. T Furuta N Shirai M Sugimoto K Ohashi T Ishizaki 2004 Pharmacogenomics of proton pump inhibitors Pharmacogenomics 5 2 181 202 (Pubitemid 38351277)
14. T Furuta N Shirai M Sugimoto A Nakamura A Hishida T Ishizaki 2005 Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies Drug Metab Pharmacokinet 20 3 153 167
15. M Kusano Y Shimoyama S Sugimoto O Kawamura M Maeda K Minashi 2004 Development and evaluation of FSSG: frequency scale for the symptoms of GERD J Gastroenterol 39 9 888 891 (Pubitemid 39409671)
16. M Kusano Y Shimoyama O Kawamura M Maeda S Kuribayashi A Nagoshi 2007 Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients Dig Dis Sci 52 7 1673 1677 (Pubitemid 46870568)
17. P Bytzer 2003 Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients Am J Gastroenterol 98 3 Suppl S31 S39
18. JG Hatlebakk PO Katz L Camacho-Lobato DO Castell 2000 Proton pump inhibitors: better acid suppression when taken before a meal than without a meal Aliment Pharmacol Ther 14 10 1267 1272
19. T Shimatani M Inoue T Kuroiwa Y Horikawa 2004 Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression Aliment Pharmacol Ther 19 1 113 122 (Pubitemid 38125644)
20. T Shimatani M Moriwaki J Xu S Tazuma M Inoue 2006 Acid-suppressive effects of rabeprazole: comparing 10 mg and 20 mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers Dig Liver Dis 38 11 802 808 (Pubitemid 44430926)
21. BB Dean AD Gano Jr K Knight JJ Ofman R Fass 2004 Effectiveness of proton pump inhibitors in nonerosive reflux disease Clin Gastroenterol Hepatol 2 8 656 664 (Pubitemid 39013424)
22. T Kamolz V Velanovich 2002 Psychological and emotional aspects of gastroesophageal reflux disease Dis Esophagus 15 3 199 203 (Pubitemid 36007842)
23. M Frazzoni E De Micheli A Grisendi V Savarino 2002 Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression Aliment Pharmacol Ther 16 5 881 886 (Pubitemid 34461756)
24. G Holtmann C Cain P Malfertheiner 1999 Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole Gastroenterology 117 1 11 16 (Pubitemid 29297614)